Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy.
Nicotinamide (1000 mg/kg; i.p.) enhanced the radiation response of the SCCVII tumour, producing an ER of almost 1.5 in a growth delay assay. Separating tumour cells as a function of fluorescent labelling with Hoechst 33342, suggested that this enhancement may be primarily a result of the elimination of acutely hypoxic cells in tumours. Nicotinamide also decreased mean arterial blood pressure in mice. These results are discussed with respect to their clinical applicability.
Horsman
M R
MR
Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus, Denmark.
Overgaard
J
J
Christensen
K L
KL
Trotter
M J
MJ
Chaplin
D J
DJ
D000818:Animals; D001562:Benzimidazoles; D001794:Blood Pressure / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy*; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D005260:Female; D005456:Fluorescent Dyes; D000860:Hypoxia / Q000503:physiopathology*; D051379:Mice; D008809:Mice, Inbred C3H; D009536:Niacinamide / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents
D001562:Benzimidazoles; D005456:Fluorescent Dyes; D011838:Radiation-Sensitizing Agents; D009536:Niacinamide; C017807:bisbenzimide ethoxide trihydrochloride